Sign in
Enrolling by invitationNo phase

Prospective Evaluation of Clinical and Radiographic Outcomes Following Total Talus Replacement (PROCLAIM)

Key facts

Who runs it
Restor3D
Where
Charlotte, United StatesSee the site
Trial code
Status
Enrolling by invitation
People taking part
50 people, planned
Started
6 Nov 2024
Expected to end
Nov 2031
Type of study
Observational
Treatments tested
  • Total Talus Replacement (TTR)
Record updated
8 January 2026

Who can take part

Age
22 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • ≥22 Years of Age
  • Scheduled to receive TTR implant for one of the following indications:
  • Avascular necrosis of the talus
  • Avascular necrosis of the talus in addition to talar collapse, cysts or non-union
  • Large, uncontained, unstable, or cystic talar osteochondral defects with risk of collapse or talar osteochondral defects not responsive to traditional treatments
  • Nonunion following talar fracture or talar extrusion, unresponsive to more conservative treatments
  • Have not had a prior Total Talus Replacement device implanted
  • Not planning to receive bilateral Total Talus Replacement devices
  • Subject signs a written informed consent form (ICF) prior to the surgical procedure

Who cannot take part

  • Surgical procedures other than those listed in the indications for use
  • Use of implant greater than 6 months from date of patient's preoperative CT scan
  • Blood supply limitations and previous infections that may prevent healing
  • Patients with foreign body sensitivity, suspected or documented material allergy or intolerance. Where material sensitivity is suspected, appropriate tests should be conducted, and sensitivity ruled out prior to implantation
  • Patients with an active local or systemic infection
  • Known history of existing malignancy, or any systemic infection, local infection, or skin compromise at the surgical site
  • Physical conditions that would eliminate adequate implant support or prevent healing, including inadequate soft tissue coverage
  • Conditions which may limit the patient's ability or willingness to restrict activities or follow directions postoperatively during the healing period
  • Degenerative changes in the tibiotalar, subtalar or talonavicular joints
  • Gross deformity in sagittal or coronal planes. More than 15 degrees of varus or valgus deformity in the coronal plane, or more than 50% subluxation anteriorly or posteriorly of the talus in the sagittal plane
  • Osteonecrosis of the calcaneus, distal tibia or navicular
  • Presence of neurological deficit which would prevent patient postoperative compliance

Where in United States

  • OrthoCarolina Research Institute, Inc.Charlotte, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

This is a Humanitarian Device Exemption (HDE) approved device. The purpose of this study is to evaluate the continued safety and probable benefit of the restor3d Total Talus Replacement device in commercial use.

The group in the trial

  • Total Talus Replacement

    50 subjects receiving the Total Talus Replacement device

    Treatment: Total Talus Replacement (TTR)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Prospective Evaluation of Clinical and Radiographic Outcomes Following Total Talus Replacement (PROCLAIM): A Multicenter, Single Arm, Prospective, Post-approval Study for Patients Who Received the restor3d TTR Device to Evaluate Safety and Probable Benefit
Record updated
8 January 2026